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Summary A mouse monoclonal antibody (IgG2b), 3CIO, was produced against the truncated epidermal
growth factor receptor (EGFR), encoded by the (type III) in-frame deletion mutation of 801 nucleotides of
EGFR affecting the external domain, known to be expressed in some human glioblastoma. As this mutation
newly generates a glycine residue at the fusion point, a 14 amino acid peptide around the fusion junction
including this glycine was chemically synthesised. and used for immunisation of (B6 x DBA/2) F1 mice. Flow
cytometric analysis showed 3C10 antibody staining of a mouse NIH/3T3 transfectant (ERM5) with the type III
EGFR deletion-mutant gene, but not one with wild-type EGFR The antibody immunoprecipitated the truncated
EGFR protein with a molecular mass of approximately 140 kDa from ERM5 cells. Immunostaining of
glioblastomas revealed binding in the case with the type III EGFR mutation, the five other specimens without
the mutation being negative despite overexpression of EGFR in some cases.
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Epidermal growth factor receptor (EGFR) gene (proto-
oncogene of v-erbB) is amplified and overexpressed in about
40% of cases of glioblastoma, the major malignant tumour of
human brain (Libermann et al., 1984; Wong et al., 1987;
Humphrey et al., 1988). This amplification is frequently
correlated with structural rearrangement of EGFR, resulting
in in-frame deletion mutations in the extracellular domains
(Humphrey et al., 1988, 1991; Yamazaki et al., 1988, 1990;
Bigner et al., 1990; Wong et al., 1992). Such deletions in EGFR
in glioblastoma have been classified into three types based on
the size and location (Humphrey et al., 1991). Type III has
been identified in about 17% of glioblastoma patients
(Humphrey et al., 1990), and is characterised by an 801 bp
in-frame deletion, which creates a unique sequence with a
glycine residue at the fusion junction between amino acid
residues 5 and 274. Since the sequence around the fusion
junction is expressed only in glioblastoma cells, it is a potential
target for diagnostic and therapeutic approaches. Humphrey
et al. (1990) reported the production of polyclonal rabbit
antibodies against type III truncated EGFR. In the study, we
generated monoclonal antibodies specifically reactive with the
fusion junction of this truncated EGFR.
Materials and methods
Cell lines and monoclonal antibody
The ERM5 cell line was obtained following transfection of
mouse NIH/3T3 fibroblast cells, which do not express wild-
type EGFR, with cDNA derived from the human glioma
xenograft GL-5 with an 801 bp in-frame type III EGFR
deletion (Yamazaki et al., 1990). NIH/3T3 cells overexpres-
sing exogeneously introduced wild-type human EGFRwere
produced as described previously (Yamazaki et al., 1990) and
are named EGFR. A431 is a human squamous cell carcinoma
cell line overexpressing intact EGFR. EGFR1 mouse
monoclonal antibody, which reacts with the external domain
of intact EGFR (170 kDa) and blocks the binding of EGF
(Waterfield et al., 1982; Carpenter, 1987), was purchased
from Dako, (Glostrup, Denmark).
Synthetic peptides
A 14 amino acid peptide corresponding to the fusion junction
(amino acid residues 1 -5, glycine, residues 274-280, and
terminal cysteine) (named Pep3 according to the report by
Humphrey et al., 1990, 1991; LEEKKGNYVVTDHC) was
chemically synthesised with a peptide synthesiser [Applied
Biosystems (ABI) 431A, Foster, CA, USA] (Figure 1), and a
portion was coupled to keyhole limplet haemocyanin (KLH).
A 17 amino acid peptide also corresponding to the fusion
junction without the glycine (LEEKKVCPRNYVVTDHC)
was synthesised as a negative control peptide. The amino acid
sequences of the synthetic peptides were confirmed using a
protein sequencer (ABI 477A).
Production of monoclonal antibody
[B6 x DBA/2 (BD)] Fl female mice were immunised
intraperitoneally (i.p.) once with 20 ,ug of Pep3 conjugated
to KLH, together with Freund's complete adjuvant, and then
with 20 ,ug of Pep3 conjugated to KLH with Freund's
incomplete adjuvant on day 29. On day 66, 50 jig of Pep3
was administered i.p., and 3 days later, spleen cells were
harvested and fused with PAI mouse myeloma cells derived
from the NS-1 cell line as described previously (Seto et al.,
1982).
Isotyping andpurification ofmonoclonal antibody
Using a Zymed mouse monoclonal isotyping kit (San
Francisco, CA, USA), the isotype of monoclonal antibodies
was determined. The anti-peptide monoclonal antibody was
purified from ascites of athymic nude mice (KSN Slc) bearing
hybridoma cells using a protein-G column (Pharmacia
Biotech, Uppsala, Sweden) according to the manufacturer's
instructions.
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Figure 1 Synthetic peptides used for immunisation. The 14 amino acid peptide (Pep3) corresponding to the fusion junction of type
III deletion mutant EGFR (amino terminal residues 1-5, glycine, residues 274-280, and a terminal cysteine) was chemically
synthesised and used for immunisation and screening monoclonal antibodies. A 17 amino acid peptide (amino terminal residues 1-
7, residues 272-280, a carboxy-terminal cysteine) was also chemically made and used for ELISA as a control.
Enzyme-linked immunosorbent assay (ELISA) and mixed
haemadsorption assay (MHA)
First screening of culture supernatants was conducted by
ELISA with synthetic peptides (Figure 1) coated on
Immunoplates (Maxisorp F96; Nunc, Roskilde, Denmark)
as described previously (Kikuchi et al., 1990), to select
antibodies with specificity to Pep3. A second screening was
carried out by MHA (Fagraeus et al., 1965; Carey et al.,
1976), using transfectants as target cells, to select antibodies
reactive with ERM5 cells.
Fluorescence activated cell sorter (FACS) analysis
Cultured human tumour cells and transfectants were
harvested with 0.02% ethylene diamine tetra-acetate
(EDTA), and 106 cells were reacted with monoclonal
antibodies and mouse MOPC-21 myeloma protein (negative
control) (20 Mug ml-1). After staining with fluorescence
isothiocyanate (FITC)-conjugated goat anti-mouse immuno-
globulin (IgG) (Fc) (Organon Teknika, Durham, NC, USA),
the cells were analysed using a FACS 440 (Becton Dickinson,
San Jose, CA, USA), as described previously (Ueda et al.,
1985).
Immunoprecipitation
Cell lines in a 75 cm2 Falcon T-flask (Becton Dickinson,
Oxnard, CA, USA) were labelled metabolically for 24 h with
0.2 mCi of L-[35S]methionine (1000 Ci mmol-1, Amersham
Life Science, Buckinghamshire, UK) in Eagle's minimum
essential medium containing 10% fetal calf serum. Prepara-
tion of cell lysates and precipitation of the immune complex
were conducted as described previously (Yoshikawa et al.,
1989). The precipitates were subjected to sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and analysed with a BAS-2000 II imaging analyser (Fuji Phot
Film, Tokyo, Japan).
Immunofluorescence staining ofxenograft and human
glioblastomas
ERM5 and EGFR transfectants were transplanted into
athymic nude mice and frozen sections were prepared from
tumours and stained by indirect immunofluorescence
methods as described previously (Yoshikawa et al., 1986).
A total of six human tumours histopathologically diagnosed
as glioblastomas were also stained. In the case of xenografts,
sections were stained after blocking endogenous Ig with goat
anti-mouse IgG (Fab) (Organon Teknika) (Nielsen et al.,
1987).
Southern blot analysis
Southern blot analysis was carried out as described
previously (James et al., 1988; Bergerheim et al., 1989).
Briefly, 10 pg aliquots of high molecular mass DNA
prepared from 15 tumours or the different cultured cells
were electrophoresed in 0.8% agarose gels and transferred to
nitrocellulose membrane. The probe used for hybridisation
was a PvuII fragment of pE7 (EGFR cDNA probe
according to Ullrich et al., 1984), which was kindly
provided by the Japanese Cancer Research Resources Bank
(Tokyo, Japan).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated from the frozen NIH/3T3
transfectants and human glioblastomas by Polytron (Kine-
matica, Littau, Switzerland) homogenisation in guanidinium
isothiocyanate buffer followed by ultracentrifugation through
caesium chloride. Single-stranded cDNA was produced using
Moloney murine leukaemia virus reverse transcriptase and
random primer with hexanucleotides. The single-stranded
cDNA was then subjected to PCR using a sense probe
(PC 66; 172-193; CTTCGGGGAGCAGCGATGCGAC)
and an antisense probe (PC 77; 1167-1146; GAATGT-
GAACGCCTGCGGCAGA) (Sugawa et al., 1990). The
PCR was standardised to 30 cycles, each consisting of
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Figure 2 Reactivity of 3C10 monoclonal antibody tested against
the immunising peptide, Pep3, and a control peptide by ELISA.
Serially diluted purified 3C10 antibody (600ygml-1) was assayed
by ELISA against immunoplates precoated with 1 Mgml-l of
synthetic peptide, Pep3 (0-0) or control peptide (O- -]).
Absorbance values represent the means of triplicate determina-
tions.
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denaturation (94°C, 1 min), annealing (first three cycles,
59°C, 2 min; second three cycles, 570C, 2 min; third three
cycles, 550C, 2 min; last 21 cycles, 530C, 2 min) and extension
(72°C, 3 min). PCR products from normal EGFR mRNA are
998 bp in length and those from type III deletion-mutant
EGFR mRNA are 197 bp.
Results
Establishment of hybridomas
Cell hybridisation was conducted after immunisation of
BDF1 female mice with the synthetic peptide corresponding
to the fusion junction encoded by the type III deletion-
mutant EGFR (Figure 1). Hybridoma supernatants were first
screened against Pep3 and the control peptide by ELISA to
select antibodies showing the relative specificity to Pep3. The
supernatants thus selected were then screened by MHA
against the ERM5 transfectant-expressing type III internal
deletion-mutant EGFR to ascertain the reactivity of the
native truncated EGFR product. Out of 576 clones, only
one clone, 3C10, was selected, and the specificity of the
antibody secreted (IgG2b) was serologically analysed as
follows.
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Reactivity of 3C10 antibody against truncated EGFR
ELISA and MHA In ELISA, the reaction of 3C10 antibody
was much stronger with Pep3 than with the control peptide
as shown in Figure 2. In MHA (Figure 3), 3C10 reacted with
ERM5 cells (NIH/3T3 cells transfected with truncated EGFR
cDNA), but not with the EGFR cells (NIH/3T3 cells
transfected with wild-type EGFR cDNA), NIH/3T3 cells or
A431 cells (high expressor of wild-type EGFR) by MHA. On
the other hand, EGFR1 antibody, which is known to be
reactive with intact EGFR (Waterfield et al., 1982; Carpenter,
1987) reacted with EGFR and A431 cells but not with ERM5
cells.
FACS ERM5 cells were stained with 3C10 antibody, but
not with EGFRI antibody against intact EGFR (Figure 4).
In contrast, EGFR and A431 cells were stained with EGFR1
antibody, but not with 3C10 antibody.
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Figure 4 FACS analysis of 3C10 and EGFR1 antibodies tested
against various cells. EDTA-harvested cells were reacted with
antibodies (20pgml-1), stained by indirect immunofluorescence
and then analysed. ERM5 cells were stained with only 3C10
antibody. EGFR and A431 cells were stained with EGFR1
antibody, but not with 3C10 antibody. NIH/3T3 cells (a negative
control) were not stained with either of the antibodies used.
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Figure 3 Reactivity of 3C10 and EGFRI antibodies tested
against various cells by MHA. Target cells used were ERM5
(NIH/3T3 transfected with type III deletion mutant EGFR),
EGFR (NIH/3T3 transfected with wilde-type EGFR) and A431
(human cell line with wild-type EGFR amplification) cell lines.
3C10 antibody (LI- -LI) reacted only with ERM5 cells. In
contrast, EGFRI antibody (0 0) reacted with EGFR and
A431 cells, but not with ERM5 and NIH/3T3 cells.
Figure 5 SDS-PAGE analysis of truncated and intact EGFR
molecules after immunoprecipitation of radiolabelled cell lysates
with 3C10 and EGFR1 antibodies. Immunoprecipitation of
lysates (100l,l) prepared from [35S]methionine-labelled cells was
conducted with EGFR1 (lane 1) and 3C10 (lane 2) antibodies
(5,ug) and a mouse myeloma protein as a negative control (lane
3). 3C10 antibody detected the band with a molecular mass (Mr)
of 140000 corresponding to the truncated EGFR in ERM5 cell
lysate. Bands with sizes smaller than 140kDa were also observed
in this lane, but they probably correspond to degradation
products of the truncated EGFR. The intact EGFR band
(170kDa) was precipitated with EGFR1 antibody from A431
and EGFR cells.
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Immunoprecipitation Cells were metabolically labelled with
L-[35S]methionine and immunoprecipitated with 3C10 anti-
body, EGFR1 antibody and negative control mouse myeloma
protein (Figure 5). 3C10 antibody specifically immunopreci-
pitated the truncated EGFR (140 kDa) from ERM5 cells, but
not from EGFR or A431 cells expressing intact EGFR. With
EGFRI antibody, intact EGFR (170 kDa) was precipitated
from EGFR and A431 cells, but not from ERM5 cells.
Immunofluorescence staining of ERM5 and EGFR xenografts
Sections of ERM5 xenograft were stained with 3C10 and
EGFR1 antibodies, and representative staining patterns are
illustrated in Figure 6. Positive staining was only detected
with 3C10 antibody. EGFR xenografts were also stained.
3C10 antibody was negative, while EGFR1 antibody was
weakly positive. The serological results obtained altogether
suggested that 3C10 antibody selectively binds to the fusion
junction encoded by type III deletion-mutant EGFR.
Immunostaining ofglioblastoma specimens with 3CJO antibody
Southern blot analysis of glioblastoma specimens High
molecular mass DNA samples from 15 glioblastoma speci-
mens were studied with the EGFR cDNA probe, the results
being partly illustrated in Figure 7. Six of 15 cases showed
amplification of EGFR and one case, patient 5, showed
amplification of rearrangement bands as well.
Detection of the type III internal deletion of EGFR in
glioblastomas RT-PCR products were generated with the
appropriate primers from glioblastoma specimens including
patient 5 showing rearrangement bands of EGFR and studied
by gel electrophoresis (see Figure 8). The 197 bp band was
observed in patient 5 and also in positive control cells,
ERM5. RT-PCR of other glioblastoma patients generated
only the 998 bp product of wild-type EGFR transcripts.
DNA sequencing of the 197 bp product confirmed that it
corresponds precisely to the type III mutant of EGFR (data
not shown).
Immunostaining with 3C10 antibody Six glioblastoma speci-
mens including one from patient 5 with deletion-mutant
EGFR were examined for immunostaining with 3C10 and
EGFR1 antibodies (Figure 9). 3C10 antibody stained the
glioblastoma of patient 5 (Figure 9a), but not that of the
other patients with or without EGFR amplification. EGFR1
Figure 6 Immunofluorescence staining of ERM5 and EGFR xenografts by 3C10 and EGFR1 antibodies. Frozen sections of
ERM5 (a, c, e) and EGFR xenografts (b, d, f) were stained with 3C10 antibody (a and b), EGFR1 antibody (c and d), or a mouse
myeloma protein (a negative control) (e and f). In each case the concentration of the antibodies used was 20ygml-1. Positive
staining of ERM5 section is evident only with 3C10 antibody, while EGFR xenograft is weakly positive with EGFR1 antibody.
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antibody stained the patient 5 tumour and three others with
EGFR amplification, suggesting production of intact EGFR
along with the truncated form in the former case. The
tumours from two patients without EGFR amplification were
not stained with EGFR1 antibody. Normal brain tissues
fiec< A6
surrounding glioblastoma were also tested, but they proved
negative with both antibodies.
Discussion
We report here the production and characterisation of a
monoclonal antibody against a portion of the truncated
EGFR encoded by type III internal deletion in-frame
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Figure 7 Southern blot analysis of genomic DNA from
glioblastoma specimens using the EGFR cDNA probe. Each
lane contains lOgg of HindIII-digested genomic DNA from
glioblastomas (patients 1-7) or human placenta. The blot was
probed with PvuII fragment of pE7 (EGFR cDNA probe 610-
3010; Ullrich et al., 1984). Tumours from six patients show
amplification of the EGFR gene and one of them (from patient 5)
demonstrates unique rearrangement bands as well).
Figure 8 RT-PCR analysis for detection of the type III internal
deletion of EGFR. RT-PCR products of EGFR mRNA from
ERM5 and EGFR transfectants and glioblastoma specimens were
separated by electrophoresis, and stained with ethidium bromide.
The mutant 197bp band is evident in the case of patient 5 and
also in ERM5 cells (positive control). All tumour samples show
the normal 998bp band.
Figure 9 Immunofluorescence staining of human glioblastoma specimens with 3C10 and EGFR1 antibodies. Frozen sections from
glioblastoma samples that had been analysed for EGFR abnormalities (see Figures 7 and 8) were stained with 3C10 (a and b) and EGFR1 (c
and d) antibodies (20pgml-). The section from patient 5 with type III deletion-mutant EGFR (a and c) bound both antibodies, whereas
that from patient 4 with amplification of wild-type EGFR (b and d) was only immunoreactive with EGFRI antibody.-Ms ko uMbody agai-e unated EGFR product
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mutated EGFR. Humphrey et al. (1990) produced rabbit anti-
synthetic peptide antiserum reacting with the fusion junction
ofthe deletion-mutant EGFR using the same peptide that we
used in this study. Subsequently, they studied the antibody
response of mice, rats, rabbits, goats and macaques to this
peptide using various immunisation protocols. In the cases of
BALB/c mice and Brown Norway rats, the antibody titre to
the mutant protein proved to be low compared with that in
rabbits. Accordingly, they performed an additional immuni-
sation with D-256 MG tumour cells expressing the type III
deletion of EGFR to enhance antibody titre (Wikstrand et al.,
1993). More recently, they reported generation of murine
monoclonal antibodies against the truncated EGFR from
these mice (Wikstrand et al., 1995).
One of the reasons why we could obtain a monoclonal
antibody by immunisation with the peptide alone in the
present study may be owing to the choice of BDF1 mice
(instead of BALB/c mice), because the mean titre in BDF1
mice was significantly higher than that in (BALB/c xC3H)
Fl mice when both were immunise with the same protocol
(unpublished observation). Another reason may be that the
immunisation peptide consisting of 14-amino acid residue
contains a B cell epitope as well as a helper epitope as
reported for synthetic immunogens for producing virus
neutralising antibody (Palker et al., 1989; Baba et al.,
1995). Consensus sequence for H-2Eb is already reported,
but that for H-2Ab is not yet determined (Rammensee et al.,
1995). Since B6 mouse expresses only H-2Ab, it is not
possible to say at present whether there is a good consensus
for it or not in this immunising peptide.
3C10 antibody showed a weak but significant reactivity
even against the control peptide by ELISA. Binding was
more specific, however, when cells expressing native type HI
deletion-mutant EGFR were used as the targets and tested by
MHA and immunoprecipitation. The results suggested that
3C10 antibody detects a conformational epitope at the fusion
junction, probably containing the newly created glycine
residue, although the exact epitope still needs to be
determined. Another important characteristic of this anti-
body is that it can stain the ERM5 transfectant and
glioblastoma specimens, expressing type III deletion-type
EGFR. It might thus find future application in immuno-
diagnosis and immunotherapy.
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